Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292057 · ClinicalTrials.gov registry record · Phase 3
Aripiprazole Effects on Alcohol Drinking and Craving
A Phase 3 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
NCT01292057 is a Phase 3 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 99 participants.
The verdict
NCT01292057, a Phase 3 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving and drinking compared to placebo depending on participant's baseline level of impulsivity.
Interventions
- DRUG Placebo
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01292057
The ClinicalTrials.gov registry entry for NCT01292057 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01292057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01292057 about?
NCT01292057 is a clinical study titled "Aripiprazole Effects on Alcohol Drinking and Craving". The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving and drinking compared to placebo depending on participant's baseline level of impulsivity.
What is the current status of trial NCT01292057?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2011-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01292057?
The interventions under investigation include: Placebo (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT01292057?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.